ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2478

Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®

Denis Choquette1, Louis Bessette2, Louis Coupal3 and Kirsten Garces4, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, 3Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 4Amgen Canada Inc., Mississauga, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-TNFs have been used to treat RA since 2000. Since the availability of new agents with different mechanisms of action around 2007, the pattern of use has evolved. The long-term biologic retention rate is a good surrogate marker for effectiveness in the clinical setting. Randomized controlled trials and their open-label extension studies provide information on drug retention in a highly selected patient population. This information, however, is of limited use when prescribing biologics in a real-world setting. Real-world databases, such as RHUMADATA®, provides an excellent opportunity to examine the changes in retention rates over time.

Objectives: To assess the retention of the first-line anti-TNF and evaluate possible differences between two eras, early (2000-2006) and late (2007-2015).

Methods: Data of biologic naïve RA patients starting an anti-TNF [adalimumab (ADA), etanercept (ETA), golimumab (GOL) or infliximab (INF)] between Jan 1, 2000, and Dec 31, 2006 (early era), and Jan 1, 2007, and Dec 2015 (late era) was extracted. Patients were followed until they stopped, changed medication, or were lost to follow-up. Collected data included demographics, concomitant medication, comorbidities, laboratory variables, PROs, and disease activity measures. Infections occurring while on treatment, biologic status (ongoing or stopped) and the reasons for biologic cessation were also extracted. Overall retention was compared using Kaplan-Meier estimates (SAS 9.4). Cox proportional hazard models were used to adjust for differences between groups at baseline.

Results:  Baseline variables were similar between the two eras, except that patients in the second era were older and had been diagnosed ~1 year sooner than first era patients. These patients were less exposed to corticosteroids, more exposed to HCQ, and had lower ESR and CRP at treatment initiation. Over the entire period, ETN had a longest mean retention time of 6.32 years versus ADA (6.24y) and INF (5.6y). This difference was statistically significant between ETN and INF (p=0.026). When analyzed in the two eras, the mean retention times of all biologics were longer in the first era (6.72y) than the second (4.7y).

Conclusion: Patients treated in the first era appear to have more severe disease, greater exposure to corticosteroids and HCQ, and better retention rate compared to patients starting an anti-TNFi after 2006. More analysis should be done to understand these differences. 

 

 


Disclosure: D. Choquette, Abbvie, Amgen, BMS, Celgene, Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 8,Abbvie, Amgen, BMS, Celgene, Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 5,Abbvie, Amgen, BMS, Celgene, Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 2; L. Bessette, Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 8,Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 5,Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 2; L. Coupal, None; K. Garces, Amgen, 1,Amgen, 3.

To cite this abstract in AMA style:

Choquette D, Bessette L, Coupal L, Garces K. Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA® [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/retention-on-adalimumab-etanercept-golimumab-and-infliximab-in-two-eras-experience-of-patients-with-rheumatoid-arthritis-from-a-real-world-database-rhumadata/. Accessed September 22, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retention-on-adalimumab-etanercept-golimumab-and-infliximab-in-two-eras-experience-of-patients-with-rheumatoid-arthritis-from-a-real-world-database-rhumadata/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology